Infant, Newborn, Diseases
Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.
Subtype terms (33)
More specific conditions that are subtypes of Infant, Newborn, Diseases in the MeSH hierarchy.
- Amniotic Band Syndrome
- Anemia, Neonatal
5 drugs (1 approved, 4 experimental)
- Asphyxia Neonatorum
3 drugs approved
- Birth Injuries
2 drugs (1 approved, 1 experimental)
- Colic
41 drugs (14 approved, 27 experimental)
- Congenital Bone Marrow Failure Syndromes
10 drugs (9 approved, 1 experimental)
- Congenital Hyperinsulinism
17 drugs (13 approved, 4 experimental)
- Cystic Fibrosis
329 drugs (163 approved, 166 experimental)
- Epilepsy, Benign Neonatal
1 drug approved
- Erythroblastosis, Fetal
4 drugs (3 approved, 1 experimental)
- Hernia, Umbilical
9 drugs (7 approved, 2 experimental)
- Hydrophthalmos
- Hyperbilirubinemia, Neonatal
14 drugs (6 approved, 8 experimental)
- Hyperostosis, Cortical, Congenital
- Ichthyosis
18 drugs (8 approved, 10 experimental)
- Infant, Premature, Diseases
94 drugs (66 approved, 28 experimental)
- Meconium Aspiration Syndrome
8 drugs (3 approved, 5 experimental)
- Mobius Syndrome
- Neonatal Abstinence Syndrome
15 drugs (8 approved, 7 experimental)
- Neonatal Sepsis
42 drugs (27 approved, 15 experimental)
- Nystagmus, Congenital
1 drug experimental
- OEIS Complex
- Ophthalmia Neonatorum
3 drugs (1 approved, 2 experimental)
- Persistent Fetal Circulation Syndrome
10 drugs (9 approved, 1 experimental)
- Rothmund-Thomson Syndrome
- Sclerema Neonatorum
- Severe Combined Immunodeficiency
42 drugs (27 approved, 15 experimental)
- Syphilis, Congenital
3 drugs (2 approved, 1 experimental)
- Thanatophoric Dysplasia
- Thrombocytopenia, Neonatal Alloimmune
5 drugs (3 approved, 2 experimental)
- Toxoplasmosis, Congenital
3 drugs (2 approved, 1 experimental)
- Vitamin K Deficiency Bleeding
1 drug approved
- Wolman Disease
14 drugs (11 approved, 3 experimental)
Drugs by status
Phase 4 trials (2)
Phase 3 trials (13)
Phase 2 trials (4)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (55)
- Genzyme
- Ionis Pharmaceuticals, Inc.
- Kastle Therapeutics, LLC
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- National Heart, Lung, and Blood Institute (NHLBI)
- World Health Organization
- Aarhus University
- University of Pennsylvania
- Brown University
- Case Western Reserve University
- Duke University
- Emory University
- Indiana University
- Katholieke Universiteit Leuven
- Ohio State University
- Osaka University
- RTI International
- Stanford University
- Tufts University
- University of Iowa
- University of Kansas
- University of New Mexico
- University of Rochester
- University of Saskatchewan
- Utrecht University
- Wayne State University
- Yale University
- University of Valencia
- University of Zurich
- +25 more
Organization Involved with Phase 2 Indications (3)
Organization Involved with Other Experimental Indications (3)